Protein aggregation and bioprocessing
- PMID: 17025275
 - PMCID: PMC2761064
 - DOI: 10.1208/aapsj080366
 
Protein aggregation and bioprocessing
Abstract
Protein aggregation is a common issue encountered during manufacture of biotherapeutics. It is possible to influence the amount of aggregate produced during the cell culture and purification process by carefully controlling the environment (eg, media components) and implementing appropriate strategies to minimize the extent of aggregation. Steps to remove aggregates have been successfully used at a manufacturing scale. Care should be taken when developing a process to monitor the compatibility of the equipment and process with the protein to ensure that potential aggregation is minimized.
References
- 
    
- US Pharmacopeia . USP/NF General Chapter<788> Particulate Matter in Injections. In: U.S. Pharmacopeia, editor. National Formulary, USP29-NF-24 (suppl 2) Rockville, MD: USP; 2006.
 
 - 
    
- Shahrokh Z, Sluzky V, Stratton PR, Eberlein GA, Wang YJ. Formulation and Delivery of Proteins and Peptides, ACS Symposium Series 567. Washington, DC: American Chemical Society; 1994. Disulfide-linked oligomerization of basic fibroblast growth factors: effect of sulfated compounds; pp. 85–99.
 
 - 
    
- Creed D. The photophysics and photochemistry of the near-UV absorbing amino acids. II. Tyrosine and its simple derivatives. Photochem Photobiol. 1984;39:563–575. doi: 10.1111/j.1751-1097.1984.tb03891.x. - DOI
 
 - 
    
- Giulivi C, Davies KJA. Dityrosine: a marker for oxidatively modified proteins and selective proteolysis. In: Packer L, editor. Methods in Enzymology. New York, NY: Academic Press; 1994. pp. 363–371. - PubMed
 
 
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
